Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

Standard Dose
325MG;200MG;16MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE is listed in Drugs@FDA under application 040860 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE Form and strength TABLET;ORAL - 325MG;200MG;16MG Sponsor INGENUS PHARMS NJ Submission history Latest submission status date: 2025-12-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE is listed in Drugs@FDA under application 040860 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE Form and strength TABLET;ORAL - 325MG;200MG;16MG Sponsor INGENUS PHARMS NJ Submission history Latest submission status date: 2025-12-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE (ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE) | Drug Monograph | MedicHelpline